[Form 3] Beyond Air, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Agios Pharmaceuticals, Inc. (AGIO) – Form 144

An affiliate has filed a Form 144 to sell up to 11,914 common shares through Morgan Stanley Smith Barney on or about 07/09/2025. The shares have an aggregate market value of $452,631.92 and represent roughly 0.02 % of the company’s 57,915,199 shares outstanding, indicating a very limited effect on the public float.

The seller acquired the shares on the same date via a cash-settled stock-option exercise. In the prior three months the same individual sold 7,000 shares (4,091 on 07/01/2025 and 2,909 on 06/24/2025) for total gross proceeds of $237,341.32.

The filing states that the insider is unaware of any undisclosed material adverse information and is complying with Rule 144 sale restrictions. Given the modest share count involved, the proposed disposition appears to be a routine liquidity move with minimal expected market impact.

Positive

• None.

Negative

• Insider share sale: Even though small, planned disposition could be viewed as a modest bearish signal by some investors.

Insights

Financial Analyst

TL;DR: Insider plans to sell 11.9k AGIO shares (0.02 % float); impact likely neutral.

The Form 144 reveals a small, pre-announced insider sale under Rule 144. The transaction’s dollar value (~$0.45 million) and percentage of outstanding shares are immaterial for a company with nearly 58 million shares. Prior recent sales total only 7,000 shares, further underscoring the low volume. Because the filing explicitly affirms no undisclosed adverse information and follows standard compliance procedures, I view the disclosure as neutral. It neither signals operational weakness nor materially alters insider ownership. Short-term price pressure should be negligible due to the modest size relative to average daily trading volume.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Goodman Robert Scott

(Last) (First) (Middle)

C/O BEYOND AIR, INC.

900 STEWART AVENUE, SUITE 301

(Street)

GARDEN CITY NY 11530

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/16/2025

3. Issuer Name and Ticker or Trading Symbol
Beyond Air, Inc. [ XAIR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.0001 per share	40,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Robert Scott Goodman	07/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many AGIO shares are being offered for sale under this Form 144?

The insider intends to sell 11,914 common shares of Agios Pharmaceuticals.

What is the estimated value of the AGIO shares to be sold?

The aggregate market value is listed as $452,631.92.

What percentage of Agios Pharmaceuticals’ outstanding shares does the sale represent?

The sale equals roughly 0.02 % of the 57,915,199 shares outstanding.

When is the approximate sale date for the AGIO shares?

The filing lists an approximate sale date of 07/09/2025 on the NASDAQ.

Has the insider sold AGIO shares recently?

Yes. In the last three months the insider sold 4,091 shares on 07/01/2025 and 2,909 shares on 06/24/2025.

What was the method of acquiring the shares now being sold?

The shares were acquired on 07/09/2025 through a stock-option exercise paid in cash.